Your browser doesn't support javascript.
loading
A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding.
Painter, Jodie N; Kaufmann, Susanne; O'Mara, Tracy A; Hillman, Kristine M; Sivakumaran, Haran; Darabi, Hatef; Cheng, Timothy H T; Pearson, John; Kazakoff, Stephen; Waddell, Nicola; Hoivik, Erling A; Goode, Ellen L; Scott, Rodney J; Tomlinson, Ian; Dunning, Alison M; Easton, Douglas F; French, Juliet D; Salvesen, Helga B; Pollock, Pamela M; Thompson, Deborah J; Spurdle, Amanda B; Edwards, Stacey L.
Afiliação
  • Painter JN; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Kaufmann S; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • O'Mara TA; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Hillman KM; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Sivakumaran H; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Darabi H; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm 17177, Sweden.
  • Cheng THT; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
  • Pearson J; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Kazakoff S; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Waddell N; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Hoivik EA; Centre for Cancer Biomarkers, Department of Clinical Science, The University of Bergen, N5020 Bergen, Norway; Department of Obstetrics and Gynecology, Haukeland University Hospital, N5021 Bergen, Norway.
  • Goode EL; Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
  • Scott RJ; Hunter Medical Research Institute, John Hunter Hospital, Newcastle, NSW 2305, Australia; Pathology North (Newcastle) John Hunter Hospital, Newcastle, NSW 2305, Australia; Centre for Information Based Medicine, University of Newcastle, NSW 2308, Australia; School of Biomedical Sciences and Pharmacy,
  • Tomlinson I; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
  • Dunning AM; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK.
  • Easton DF; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.
  • French JD; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Salvesen HB; Centre for Cancer Biomarkers, Department of Clinical Science, The University of Bergen, N5020 Bergen, Norway; Department of Obstetrics and Gynecology, Haukeland University Hospital, N5021 Bergen, Norway.
  • Pollock PM; Institute of Health and Biomedical Innovation and School of Biomedical Science, Queensland University of Technology at the Translation Research Institute, Brisbane 4102, Australia.
  • Thompson DJ; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.
  • Spurdle AB; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Edwards SL; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia. Electronic address: stacey.edwards@qimrberghofer.edu.au.
Am J Hum Genet ; 98(6): 1159-1169, 2016 06 02.
Article em En | MEDLINE | ID: mdl-27259051
ABSTRACT
A recent meta-analysis of multiple genome-wide association and follow-up endometrial cancer case-control datasets identified a novel genetic risk locus for this disease at chromosome 14q32.33. To prioritize the functional SNP(s) and target gene(s) at this locus, we employed an in silico fine-mapping approach using genotyped and imputed SNP data for 6,608 endometrial cancer cases and 37,925 controls of European ancestry. Association and functional analyses provide evidence that the best candidate causal SNP is rs2494737. Multiple experimental analyses show that SNP rs2494737 maps to a silencer element located within AKT1, a member of the PI3K/AKT/MTOR intracellular signaling pathway activated in endometrial tumors. The rs2494737 risk A allele creates a YY1 transcription factor-binding site and abrogates the silencer activity in luciferase assays, an effect mimicked by transfection of YY1 siRNA. Our findings suggest YY1 is a positive regulator of AKT1, mediating the stimulatory effects of rs2494737 increasing endometrial cancer risk. Identification of an endometrial cancer risk allele within a member of the PI3K/AKT signaling pathway, more commonly activated in tumors by somatic alterations, raises the possibility that well tolerated inhibitors targeting this pathway could be candidates for evaluation as chemopreventive agents in individuals at high risk of developing endometrial cancer.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Uterinas / Cromossomos Humanos Par 14 / Neoplasias do Endométrio / Fosfatidilinositol 3-Quinases / Polimorfismo de Nucleotídeo Único / Proteínas Proto-Oncogênicas c-akt / Fator de Transcrição YY1 Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Uterinas / Cromossomos Humanos Par 14 / Neoplasias do Endométrio / Fosfatidilinositol 3-Quinases / Polimorfismo de Nucleotídeo Único / Proteínas Proto-Oncogênicas c-akt / Fator de Transcrição YY1 Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article